EWTX Edgewise Therapeutics, Inc.
Stock · NasdaqGS · United States · Healthcare · US28036F1057
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Edgewise Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
45.04 USD
+15.87%
52-week range
16.70 – 48.51
Dividend yield—
Market cap4.9B
NowoTrade score
26 Grade C
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:02. Information, not advice.
Results
Next results
25 Feb 2027
in 110 days · 16:00 · estimate -0.47
Last results
9.65 vs 2.51 estimated
04 Nov 2026 · Beat +284.0%
Beat the estimate
6 of 12
4 missed · 2 in line
Average surprise
+25.4%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | -0.47 | — | — | Upcoming |
| 04 Nov 2026 16:00 | 2.51 | 9.65 | +284.0% | Beat |
| 06 Aug 2026 08:00 | -0.47 | -0.53 | -12.2% | Miss |
| 07 May 2026 08:00 | -0.48 | -0.46 | +5.2% | Beat |
| 26 Feb 2026 08:00 | -0.44 | -0.47 | -6.3% | Miss |
| 06 Nov 2025 08:00 | -0.40 | -0.39 | +2.8% | Beat |
| 07 Aug 2025 08:00 | -0.42 | -0.34 | +18.3% | Beat |
| 08 May 2025 08:00 | -0.42 | -0.43 | -2.1% | Miss |
| 03 Mar 2025 08:00 | -0.42 | -0.42 | +0.5% | In line |
| 07 Nov 2024 08:00 | -0.37 | -0.36 | +3.3% | Beat |
| 08 Aug 2024 08:00 | -0.34 | -0.34 | +0.6% | In line |
| 09 May 2024 08:00 | -0.41 | -0.33 | +19.1% | Beat |
| 22 Feb 2024 08:00 | -0.43 | -0.47 | -8.4% | Miss |
| 09 Nov 2023 08:00 | -0.40 | -0.41 | -3.0% | Miss |
| 10 Aug 2023 08:00 | -0.40 | -0.34 | +14.1% | Beat |
| 11 May 2023 08:00 | -0.35 | -0.36 | -3.7% | Miss |
| 23 Feb 2023 08:00 | -0.33 | -0.31 | +6.9% | Beat |
| 03 Nov 2022 08:00 | -0.36 | -0.34 | +4.2% | Beat |
| 04 Aug 2022 08:00 | -0.32 | -0.32 | +1.5% | Beat |
| 11 May 2022 08:00 | -0.28 | -0.30 | -6.2% | Miss |
| 24 Feb 2022 08:00 | -0.26 | -0.26 | -0.7% | In line |
| 10 Nov 2021 08:00 | -0.24 | -0.26 | -6.7% | Miss |
| 09 Aug 2021 09:00 | -0.17 | -0.21 | -22.6% | Miss |
| 13 May 2021 16:00 | -0.15 | -0.14 | +7.7% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -167.8M | — | -1.63 | -288.1% | -144.1M |
| 2024 | 0 | — | -133.8M | — | -0.42 | +73.2% | -110.3M |
| 2023 | 0 | — | -100.2M | — | -1.57 | -406.5% | -97.7M |
| 2022 | 0 | — | -67.6M | — | -0.31 | — | -58.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 29 Feb 2024 | 16.99 | 17.22 | 16.03 | 16.33 | -1.92% | 864,200 | |
| 28 Feb 2024 | 16.92 | 17.09 | 16.11 | 16.65 | -1.19% | 784,900 | |
| 27 Feb 2024 | 17.22 | 17.70 | 16.82 | 16.85 | -1.12% | 968,400 | |
| 26 Feb 2024 | 17.29 | 17.67 | 16.82 | 17.04 | -1.39% | 494,400 | |
| 23 Feb 2024 | 18.38 | 18.38 | 17.27 | 17.28 | -0.52% | 467,400 | |
| 22 Feb 2024 | 17.51 | 18.44 | 17.11 | 17.37 | -0.74% | 722,100 | |
| 21 Feb 2024 | 17.66 | 17.88 | 17.41 | 17.50 | -0.40% | 584,800 | |
| 20 Feb 2024 | 17.13 | 18.25 | 17.04 | 17.57 | +1.15% | 1,074,500 | |
| 16 Feb 2024 | 18.31 | 18.42 | 17.20 | 17.37 | -5.19% | 806,700 | |
| 15 Feb 2024 | 18.22 | 18.63 | 17.66 | 18.32 | +2.12% | 1,508,200 | |
| 14 Feb 2024 | 19.12 | 19.56 | 17.90 | 17.94 | -5.13% | 517,700 | |
| 13 Feb 2024 | 18.40 | 18.95 | 17.64 | 18.91 | -0.21% | 794,300 | |
| 12 Feb 2024 | 19.27 | 19.95 | 18.83 | 18.95 | -2.67% | 754,200 | |
| 09 Feb 2024 | 20.00 | 20.69 | 19.37 | 19.47 | -1.72% | 895,300 | |
| 08 Feb 2024 | 20.00 | 20.12 | 19.31 | 19.81 | -0.80% | 731,900 | |
| 07 Feb 2024 | 19.83 | 20.01 | 19.23 | 19.97 | +1.73% | 714,000 | |
| 06 Feb 2024 | 18.75 | 19.65 | 18.75 | 19.63 | +4.64% | 470,800 | |
| 05 Feb 2024 | 18.33 | 18.93 | 17.77 | 18.76 | +1.13% | 743,400 | |
| 02 Feb 2024 | 18.66 | 19.03 | 18.23 | 18.55 | -3.28% | 537,000 | |
| 01 Feb 2024 | 17.95 | 19.50 | 17.88 | 19.18 | +7.57% | 993,200 | |
| 31 Jan 2024 | 17.12 | 18.28 | 16.76 | 17.83 | +3.48% | 541,900 | |
| 30 Jan 2024 | 17.51 | 17.80 | 17.05 | 17.23 | -1.77% | 448,300 | |
| 29 Jan 2024 | 16.49 | 17.57 | 16.19 | 17.54 | +6.17% | 932,100 | |
| 26 Jan 2024 | 16.01 | 16.59 | 15.70 | 16.52 | +5.02% | 1,734,700 | |
| 25 Jan 2024 | 15.43 | 15.93 | 15.16 | 15.73 | +2.68% | 888,300 |
Page 28 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring (opens in a new tab) 05 Nov 2026 13:00
- Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51 (opens in a new tab) Benzinga · 05 Nov 2026 09:44
- Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 Meeting (opens in a new tab) Benzinga · 05 Nov 2026 09:12
- Edgewise Therapeutics Reports Third Quarter 2026 Financial Results (opens in a new tab) 04 Nov 2026 21:01
- Edgewise Therapeutics Q3 Adj. EPS $(0.19) Misses $2.48 Estimate (opens in a new tab) Benzinga · 04 Nov 2026 17:44
- Servier’s $1.55bn muscular dystrophy drug fails Phase II BMD trial (opens in a new tab) Clinical Trials Arena · 04 Nov 2026 12:35
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (opens in a new tab) 02 Nov 2026 13:00
- Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says (opens in a new tab) MT Newswires · 27 Oct 2026 15:53
- Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy? (opens in a new tab) Simply Wall St. · 15 Oct 2026 03:11
- Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value? (opens in a new tab) Simply Wall St. · 03 Oct 2026 04:11
- Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says (opens in a new tab) MT Newswires · 25 Sep 2026 18:42
- Biotech Options Buzz: UTHR, NMRA, EWTX (opens in a new tab) Schaeffer's Investment Research · 18 Sep 2026 16:46
- Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified? (opens in a new tab) Simply Wall St. · 21 Jul 2026 11:08
- Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive (opens in a new tab) Pharmaceutical Technology · 07 Jul 2026 17:52
- Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now? (opens in a new tab) Insider Monkey · 29 Jun 2026 20:32
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 38.87 USD
- Market cap
- 4.9B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 3.8 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 5.37× | Good | 31.09× |
| P/E (forward) | -24.1× | Weak | 14.98× |
| Price / book | 9.16× | Weak | 4× |
| EV / EBITDA | -16.69× | Weak | 13.22× |
| Free cash flow yield | -1.9% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 59.2% |
| Operating margin | 0% | Weak | 7.8% |
| Net margin | 0% | Weak | 3.2% |
| Return on equity | -38% | Weak | 5.8% |
| Return on assets | -25% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.46× |
| Current ratio | 16.24× | Good | 2.35× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow EWTX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.